CHA 2 DS 2 -VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention
Restricted accessResearch articleFirst published online October, 2016
CHA 2 DS 2 -VASc Score is a Predictor of No-Reflow in Patients With ST-Segment Elevation Myocardial Infarction Who Underwent Primary Percutaneous Intervention
Thrombosis and distal embolization play crucial role in the etiology of no-reflow. CHA2DS2-VASc score is used to estimate the risk of thromboembolism in patients with atrial fibrillation. We tested the hypothesis that CHA2DS2-VASc can predict no-reflow among patients who underwent primary percutaneous coronary intervention (PCI). A total number of 2375 consecutive patients with ST-segment elevation myocardial infarction were assessed for the study. Patients were divided into 2 groups as no-reflow (n = 111) and control (n = 1670) groups according to post-PCI no-reflow status. CHA2DS2-VASc scores were calculated for all patients. CHA2DS2-VASc scores were significantly higher in the no-reflow group compared to the control group. After a multivariate regression analysis, CHA2DS2-VASc score remained as an independent predictor (odds ratio: 1.58, 95% confidence interval: 1.33-1,88, P < .001) of no-reflow. Receiver–operating characteristics analysis revealed the cutoff value of CHA2DS2-VASc score ≥2 as a predictor of no-reflow with a sensitivity of 66% and a specificity of 59%. Moreover, in-hospital mortality was also associated with significantly higher CHA2DS2-VASc scores. In conclusion, CHA2DS2-VASc score is associated with higher risk of no-reflow and in-hospital mortality rates in patients who underwent primary PCI.
JaffeRCharronTPuleyGDickAStraussBH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117(24):3152–3156.
2.
DuranteACamiciPG. Novel insights into an “old” phenomenon: the no reflow. Int J Cardiol. 2015;187:273–280.
3.
MorishimaISoneTOkumuraK. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36(4):1202–1209.
4.
HarrisonRWAggarwalAOuF. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2012;111(2):178–184.
5.
NdrepepaGTirochKFusaroM. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55(21):2383–2389.
6.
LipGYHNieuwlaatRPistersRLaneDACrijnsHJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest. 2010;137(2):263–272.
7.
CammAJLipGYHDe CaterinaR. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.
8.
ChuaS-KLoH-MChiuC-ZShyuK-G. Use of CHADS2 and CHA2DS2-VASc scores to predict subsequent myocardial infarction, stroke, and death in patients with acute coronary syndrome: data from taiwan acute coronary syndrome full spectrum registry. PLoS One. 2014;9(10):e111167.
9.
StegPGJamesSKAtarD. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–2619.
10.
NiccoliGBurzottaFGaliutoLCreaF. Myocardial No-Reflow in Humans. J Am Coll Cardiol. 2009;54(4):281–292.
11.
TIMI study. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985;312(14):932–936.
12.
GibsonCCannonCMurphyS. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000;101(2):125–130.
13.
ManciaGFagardRNarkiewiczK. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014;23(1):3–16.
14.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care2014;37(suppl 1):81–90.
15.
CockcroftMHGaultDW. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.
16.
CarrickDOldroydKGMcEntegartMHaigCPetrieMCEteibaH. A randomized trial of deferred stenting versus immediate stenting to prevent No- or slow-reflow in acute ST-segment elevation myocardial infarction (DEFER-STEMI). J. Am. Coll. Cardiol. 2014;63(20):2088–98.
17.
ChenYWangCYangX. Independent no-reflow predictors in female patients with ST-elevation acute myocardial infarction treated with primary percutaneous coronary intervention. Heart Vessels. 2012;27(3):243–249.
18.
Vaknin-AssaHAssaliAFuchsSZafrirNKornowskiR. Prognostic impact of sex on clinical outcomes following emergent coronary angioplasty in acute myocardial infarction. Coron Artery Dis. 2006;17(1):1–5.
19.
Al-ThaniHAEl-MenyarAZubaidM. Peripheral arterial disease in patients presenting with acute coronary syndrome in six middle eastern countries. Int J Vasc Med. 2011;2011:815902.
20.
ChaM-JLeeHSKimYDNamHSHeoJH. The association between asymptomatic coronary artery disease and CHADS2 and CHA2 DS2 -VASc scores in patients with stroke. Eur J Neurol. 2013;20(9):1256–1263.
21.
KimJChaM-JLeeDH. The association between cerebral atherosclerosis and arterial stiffness in acute ischemic stroke. Atherosclerosis. 2011;219(2):887–891.
22.
NiccoliGScaloneGLermanACreaF. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J. 2016;37(13):1024–1033.
23.
KaulS. The “no reflow” phenomenon following acute myocardial infarction: Mechanisms and treatment options. J Cardiol. 2014;64(2):77–85.
24.
IwakuraKItoHIkushimaM. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol. 2003;41(1):1–7.
25.
ColletJ-PMontalescotG. The acute reperfusion management of STEMI in patients with impaired glucosetolerance and type 2 diabetes. Diabetes Vasc Dis Res. 2005;2(3):136–143.
26.
Di CarliMFJanisseJGrunbergerGAgerJ. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol. 2003;41(8):1387–1393.
CreaFCamiciPGBairey MerzCN. Coronary microvascular dysfunction: an update. Eur Heart J. 2014;35(17):1101–1111.
29.
CetinMCakiciMZencirC. Prediction of coronary artery disease severity using CHADS2 and CHA2DS2-VASc scores and a newly defined CHA2DS2-VASc-HS score. Am J Cardiol. 2014;113(6):950–956.
30.
ChanY-HYiuK-HLauK-K. The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: Role of incorporating PR prolongation. Atherosclerosis. 2014;237(2):504–513.
31.
MagroMNautaSTSimsekC. Usefulness of the SYNTAX Score to Predict “No Reflow” in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Am J Cardiol. 2012;109(5):601–606.
